Open Medicine
(Oct 2018)
Is monitoring mean platelet volume necessary in breast cancer patients?
Taskaynatan Halil,
Alacacioglu Ahmet,
Kucukzeybek Yuksel,
Varol Umut,
Yildiz Yasar,
Salman Tarik,
Oflazoglu Utku,
Tarhan Mustafa Oktay
Affiliations
Taskaynatan Halil
Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
Alacacioglu Ahmet
Izmir Katip Celebi University Ataturk Training and Research Hospital, Medical Oncology Clinic, 35360, Izmir, Turkey
Kucukzeybek Yuksel
Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
Varol Umut
Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
Yildiz Yasar
Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
Salman Tarik
Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
Oflazoglu Utku
Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
Tarhan Mustafa Oktay
Institute of Oncology, Dokuz Eylul University, Izmir, Turkey
DOI
https://doi.org/10.1515/med-2018-0067
Journal volume & issue
Vol. 13,
no. 1
pp.
450
– 455
Abstract
Read online
Mean platelet volume (MPV) is a parameter that increases during thrombotic and cardiovascular events. Tamoxifen (Tmx) and aromatase inhibitors (AIs), which are adjuvant endocrine therapies, may cause serious side effects, such as vascular thrombosis. The present study investigated the changes in MPV values of breast cancer patients receiving long-term adjuvant hormone therapy and the relationship of MPV with adverse effects of hormonotherapy.
Keywords
WeChat QR code
Close